結節性硬化症治療薬の世界市場レポート 2025年

結節性硬化症治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は8.4％で、11億9,000万米ドルに成長します。予測期間中に予想される成長の原動力となるのは、個別化医療への注目の高まり、希少疾患治療薬の開発投資の増加、患者擁護・支援ネットワークの拡大、カンナビジオールベースの治療法の出現、遺伝子標的治療の進展などです。予測期間を形成すると予想される主な動向には、併用療法アプローチの成長、希少疾患治療薬の規制迅速化、カンナビジオール（エピディオレックス）の採用増加、疾患修飾療法の開発、結節性硬化症複合体（TSC）の管理におけるデジタルヘルス技術の統合などがあります。

慢性疾患の罹患率の増加は、今後数年間の結節性硬化症治療薬市場の拡大に大きく寄与すると予想されます。慢性疾患とは、徐々に発症し、継続的な治療を必要とする長期にわたる病状です。これには、糖尿病、心臓病、高血圧、関節炎、慢性呼吸器疾患、がん、肥満などが含まれます。これらの疾病の増加は、不健康な食生活や運動不足などのライフスタイル要因によるところが大きく、長期的な健康合併症を引き起こします。結節性硬化症治療薬は、結節性硬化症複合体（TSC）の根本原因に対処し、腫瘍抑制と発作制御のための効果的な選択肢を提供することで、慢性疾患管理をサポートします。これらの薬剤は、長期的な症状管理を可能にし、病院を受診する頻度を減らすことで、患者の転帰を改善します。例えば、2024年6月、英国の国民保健サービス（NHS）は、一般開業医に登録された患者のうち、2023年に非糖尿病性高血糖症または糖尿病予備軍と診断されたのは361万5,330人で、2022年の306万5,825人から18％増加したと報告しました。その結果、慢性疾患の罹患率の増加が結節性硬化症治療薬市場の成長を促進しています。

結節性硬化症治療薬市場の企業は、哺乳類ラパマイシン標的（mTOR）阻害剤など、腫瘍の縮小、発作の抑制、根本的な疾患メカニズムの解明を目的とした治療法の開発を通じて、イノベーションに注力しています。mTOR阻害剤は、成長、増殖、生存などの主要な細胞プロセスを制御するmTORタンパク質をブロックする一群の医薬品です。例えば、2024年8月、米国の製薬会社Upsher-Smith Laboratories LLCは、結節性硬化症複合体（TSC）患者向けに、2.5mg、5mg、7.5mg、10mgの複数の強さのTORPENZ（エベロリムス）錠剤を発売しました。トルペンズは、TSCにおける異常な細胞増殖の原因となる過剰なmTOR経路を阻害することにより機能し、良性腫瘍を縮小させ、発作などの関連症状を管理するのに役立ちます。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界結節性硬化症治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の結節性硬化症治療薬市場：成長率分析
• 世界の結節性硬化症治療薬市場の実績：規模と成長, 2019-2024
• 世界の結節性硬化症治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界結節性硬化症治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の結節性硬化症治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 標的療法
• 免疫療法
• 治療
• 世界の結節性硬化症治療薬市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 静脈内
• 皮下
• 世界の結節性硬化症治療薬市場治療段階別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 初期診断
• 慢性疾患管理
• 再発管理
• 世界の結節性硬化症治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の結節性硬化症治療薬市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• ホームケア
• 専門クリニック
• その他のエンドユーザー
• 世界の結節性硬化症治療薬市場標的療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 哺乳類ラパマイシン標的タンパク質（mTOR）阻害剤
• 血管内皮増殖因子（VEGF）阻害剤
• チロシンキナーゼ阻害剤
• 世界の結節性硬化症治療薬市場免疫療法の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• モノクローナル抗体
• 免疫チェックポイント阻害剤
• サイトカイン療法
• 世界の結節性硬化症治療薬市場、治療のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗てんかん薬
• コルチコステロイド
• 行動療法薬

第7章 地域別・国別分析

• 世界の結節性硬化症治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の結節性硬化症治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 結節性硬化症治療薬市場：競合情勢
• 結節性硬化症治療薬市場：企業プロファイル
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • The Johns Hopkins University Overview, Products and Services, Strategy and Financial Analysis
  • Yale University Overview, Products and Services, Strategy and Financial Analysis
  • Jazz Pharmaceuticals Public Limited Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Washington University School of Medicine
• Dr. Reddy's Laboratories
• H. Lundbeck A/S
• Shijiazhuang Yiling Pharmaceutical Co. Ltd
• BridgeBio Pharma Inc.
• Globela Pharma Pvt Ltd.
• Noema Pharma AG
• Aucta Pharmaceuticals Inc.
• Aeovian Pharmaceuticals Inc.
• Anavex Life Sciences Corp.
• Aucta Pharmaceuticals Inc.
• Par Pharmaceutical
• GRIN Therapeutics Inc.
• Ovid Therapeutics Inc.
• Cassava Sciences Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 結節性硬化症治療薬市場2029：新たな機会を提供する国
• 結節性硬化症治療薬市場2029：新たな機会を提供するセグメント
• 結節性硬化症治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Tuberous sclerosis drugs are medications used to treat the symptoms of tuberous sclerosis complex (TSC), a genetic disorder that leads to the formation of benign tumors in various organs, particularly the brain, kidneys, heart, lungs, and skin. The primary objective of these treatments is to reduce tumor size, control seizures, and manage related symptoms, ultimately enhancing the quality of life by addressing the underlying cellular abnormalities.

The main classes of drugs used in tuberous sclerosis treatment include targeted therapy, immunotherapy, and symptomatic treatments. Targeted therapy involves using medications that specifically focus on molecular pathways responsible for tumor growth in TSC. These drugs can be administered through various routes, including oral, intravenous, and subcutaneous methods. Treatment generally occurs in stages, such as initial diagnosis, chronic management, and management of recurrent symptoms. Distribution occurs through hospital pharmacies, retail pharmacies, and online pharmacies, with end-users including hospitals, home care providers, specialty clinics, and others.

The tuberous sclerosis drug market research report is one of a series of new reports from The Business Research Company that provides tuberous sclerosis drug market statistics, including tuberous sclerosis drug industry global market size, regional shares, competitors with a tuberous sclerosis drug market share, detailed tuberous sclerosis drug market segments, market trends and opportunities, and any further data you may need to thrive in the tuberous sclerosis drug industry. This tuberous sclerosis drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The tuberous sclerosis drug market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.86 billion in 2025 at a compound annual growth rate (CAGR) of 8.7%. The growth observed during the historic period can be attributed to the increasing awareness of rare genetic disorders, the rising prevalence of epilepsy among tuberous sclerosis complex (TSC) patients, higher rates of clinical diagnosis, the availability of anticonvulsants, and expanding research on neurocutaneous syndromes.

The tuberous sclerosis drug market size is expected to see strong growth in the next few years. It will grow to $1.19 billion in 2029 at a compound annual growth rate (CAGR) of 8.4%. The anticipated growth in the forecast period is expected to be driven by a greater focus on personalized medicine, increased investment in the development of drugs for rare diseases, the expansion of patient advocacy and support networks, the emergence of cannabidiol-based treatments, and the progress in gene-targeted therapies. Key trends expected to shape the forecast period include the growth of combination therapy approaches, regulatory fast-tracking for rare disease drugs, rising adoption of cannabidiol (Epidiolex), the development of disease-modifying therapies, and the integration of digital health technologies in the management of tuberous sclerosis complex (TSC).

The growing incidence of chronic diseases is expected to significantly contribute to the expansion of the tuberous sclerosis drug market in the coming years. Chronic diseases are long-lasting medical conditions that usually develop gradually and require continuous care. These include diabetes, heart disease, hypertension, arthritis, chronic respiratory conditions, cancer, and obesity. The rise in these diseases is largely attributed to lifestyle factors such as unhealthy diets and physical inactivity, which lead to long-term health complications. Tuberous sclerosis drugs support chronic disease management by addressing the root causes of tuberous sclerosis complex (TSC), offering effective options for tumor suppression and seizure control. These medications improve patient outcomes by enabling long-term symptom management and reducing the frequency of hospital visits. For instance, in June 2024, the UK's National Health Service (NHS) reported that 3,615,330 individuals registered with general practitioners were diagnosed with non-diabetic hyperglycemia or pre-diabetes in 2023-an 18% increase from 3,065,825 cases in 2022. As a result, the increasing incidence of chronic diseases is propelling the growth of the tuberous sclerosis drug market.

Companies in the tuberous sclerosis drug market are focusing on innovation through the development of treatments such as mammalian target of rapamycin (mTOR) inhibitors to reduce tumor size, control seizures, and target the underlying disease mechanisms. mTOR inhibitors are a class of medications that block the mTOR protein, which regulates key cellular processes including growth, proliferation, and survival. For example, in August 2024, Upsher-Smith Laboratories LLC, a U.S.-based pharmaceutical firm, introduced TORPENZ (everolimus) tablets in multiple strengths-2.5 mg, 5 mg, 7.5 mg, and 10 mg-for patients with tuberous sclerosis complex (TSC). TORPENZ functions by inhibiting the overactive mTOR pathway responsible for abnormal cell growth in TSC, helping to shrink benign tumors and manage associated symptoms such as seizures.

In February 2025, Immedica Pharma AB, a Sweden-based pharmaceutical company, acquired Marinus Pharmaceuticals Inc. for $151 million. This acquisition aims to expand Immedica's footprint in the rare seizure disorder segment and enhance its neuroscience drug portfolio, particularly with the inclusion of ganaxolone. The move supports Immedica's strategic objective to broaden its global presence and strengthen its pipeline for treating rare central nervous system (CNS) conditions. Marinus Pharmaceuticals Inc., based in the U.S., is a biopharmaceutical company focused on developing innovative therapies for rare seizure disorders, including those linked to tuberous sclerosis.

Major players in the tuberous sclerosis drug market are Johnson & Johnson, Novartis AG, The Johns Hopkins University, Yale University, Jazz Pharmaceuticals Public Limited Company, Washington University School of Medicine, Dr. Reddy's Laboratories, H. Lundbeck A/S, Shijiazhuang Yiling Pharmaceutical Co. Ltd, BridgeBio Pharma Inc., Globela Pharma Pvt Ltd., Noema Pharma AG, Aucta Pharmaceuticals Inc., Aeovian Pharmaceuticals Inc., Anavex Life Sciences Corp., Aucta Pharmaceuticals Inc., Par Pharmaceutical, GRIN Therapeutics Inc., Ovid Therapeutics Inc., and Cassava Sciences Inc.

North America was the largest region in the tuberous sclerosis drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in tuberous sclerosis drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the tuberous sclerosis drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The tuberous sclerosis drug market consists of sales of topical treatments, psychiatric medications, and supportive care therapies used to manage the various symptoms and complications of tuberous sclerosis complex. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Tuberous Sclerosis Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on tuberous sclerosis drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for tuberous sclerosis drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The tuberous sclerosis drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Targeted Therapy; Immunotherapy; Symptomatic Treatment
• 2) By Route Of Administration: Oral; Intravenous; Subcutaneous
• 3) By Treatment Stage: Initial Diagnosis; Chronic Management; Recurrent Management
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 5) By End-Users: Hospitals; Homecare; Specialty Clinics; Other End-Users
• Subsegments:
• 1) By Targeted Therapy: Mammalian Target Of Rapamycin (mTOR) Inhibitors; Vascular Endothelial Growth Factor (VEGF) Inhibitors; Tyrosine Kinase Inhibitors
• 2) By Immunotherapy: Monoclonal Antibodies; Immune Checkpoint Inhibitors; Cytokine Therapy
• 3) By Symptomatic Treatment: Antiepileptic Drugs; Corticosteroids; Behavioral Therapy Medications
• Companies Mentioned: Johnson & Johnson; Novartis AG; The Johns Hopkins University; Yale University; Jazz Pharmaceuticals Public Limited Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Tuberous Sclerosis Drug Market Characteristics

3. Tuberous Sclerosis Drug Market Trends And Strategies

4. Tuberous Sclerosis Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Tuberous Sclerosis Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Tuberous Sclerosis Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Tuberous Sclerosis Drug Market Growth Rate Analysis
• 5.4. Global Tuberous Sclerosis Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Tuberous Sclerosis Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Tuberous Sclerosis Drug Total Addressable Market (TAM)

6. Tuberous Sclerosis Drug Market Segmentation

• 6.1. Global Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Targeted Therapy
• Immunotherapy
• Symptomatic Treatment
• 6.2. Global Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Subcutaneous
• 6.3. Global Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Initial Diagnosis
• Chronic Management
• Recurrent Management
• 6.4. Global Tuberous Sclerosis Drug Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Tuberous Sclerosis Drug Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End-Users
• 6.6. Global Tuberous Sclerosis Drug Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Mammalian Target Of Rapamycin (mTOR) Inhibitors
• Vascular Endothelial Growth Factor (VEGF) Inhibitors
• Tyrosine Kinase Inhibitors
• 6.7. Global Tuberous Sclerosis Drug Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Immune Checkpoint Inhibitors
• Cytokine Therapy
• 6.8. Global Tuberous Sclerosis Drug Market, Sub-Segmentation Of Symptomatic Treatment, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiepileptic Drugs
• Corticosteroids
• Behavioral Therapy Medications

7. Tuberous Sclerosis Drug Market Regional And Country Analysis

• 7.1. Global Tuberous Sclerosis Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Tuberous Sclerosis Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Tuberous Sclerosis Drug Market

• 8.1. Asia-Pacific Tuberous Sclerosis Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Tuberous Sclerosis Drug Market

• 9.1. China Tuberous Sclerosis Drug Market Overview
• 9.2. China Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Tuberous Sclerosis Drug Market

• 10.1. India Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Tuberous Sclerosis Drug Market

• 11.1. Japan Tuberous Sclerosis Drug Market Overview
• 11.2. Japan Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Tuberous Sclerosis Drug Market

• 12.1. Australia Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Tuberous Sclerosis Drug Market

• 13.1. Indonesia Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Tuberous Sclerosis Drug Market

• 14.1. South Korea Tuberous Sclerosis Drug Market Overview
• 14.2. South Korea Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Tuberous Sclerosis Drug Market

• 15.1. Western Europe Tuberous Sclerosis Drug Market Overview
• 15.2. Western Europe Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Tuberous Sclerosis Drug Market

• 16.1. UK Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Tuberous Sclerosis Drug Market

• 17.1. Germany Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Tuberous Sclerosis Drug Market

• 18.1. France Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Tuberous Sclerosis Drug Market

• 19.1. Italy Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Tuberous Sclerosis Drug Market

• 20.1. Spain Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Tuberous Sclerosis Drug Market

• 21.1. Eastern Europe Tuberous Sclerosis Drug Market Overview
• 21.2. Eastern Europe Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Tuberous Sclerosis Drug Market

• 22.1. Russia Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Tuberous Sclerosis Drug Market

• 23.1. North America Tuberous Sclerosis Drug Market Overview
• 23.2. North America Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Tuberous Sclerosis Drug Market

• 24.1. USA Tuberous Sclerosis Drug Market Overview
• 24.2. USA Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Tuberous Sclerosis Drug Market

• 25.1. Canada Tuberous Sclerosis Drug Market Overview
• 25.2. Canada Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Tuberous Sclerosis Drug Market

• 26.1. South America Tuberous Sclerosis Drug Market Overview
• 26.2. South America Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Tuberous Sclerosis Drug Market

• 27.1. Brazil Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Tuberous Sclerosis Drug Market

• 28.1. Middle East Tuberous Sclerosis Drug Market Overview
• 28.2. Middle East Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Tuberous Sclerosis Drug Market

• 29.1. Africa Tuberous Sclerosis Drug Market Overview
• 29.2. Africa Tuberous Sclerosis Drug Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Tuberous Sclerosis Drug Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Tuberous Sclerosis Drug Market, Segmentation By Treatment Stage, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Tuberous Sclerosis Drug Market Competitive Landscape And Company Profiles

• 30.1. Tuberous Sclerosis Drug Market Competitive Landscape
• 30.2. Tuberous Sclerosis Drug Market Company Profiles
  • 30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. The Johns Hopkins University Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Yale University Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Jazz Pharmaceuticals Public Limited Company Overview, Products and Services, Strategy and Financial Analysis

31. Tuberous Sclerosis Drug Market Other Major And Innovative Companies

• 31.1. Washington University School of Medicine
• 31.2. Dr. Reddy's Laboratories
• 31.3. H. Lundbeck A/S
• 31.4. Shijiazhuang Yiling Pharmaceutical Co. Ltd
• 31.5. BridgeBio Pharma Inc.
• 31.6. Globela Pharma Pvt Ltd.
• 31.7. Noema Pharma AG
• 31.8. Aucta Pharmaceuticals Inc.
• 31.9. Aeovian Pharmaceuticals Inc.
• 31.10. Anavex Life Sciences Corp.
• 31.11. Aucta Pharmaceuticals Inc.
• 31.12. Par Pharmaceutical
• 31.13. GRIN Therapeutics Inc.
• 31.14. Ovid Therapeutics Inc.
• 31.15. Cassava Sciences Inc.

32. Global Tuberous Sclerosis Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Tuberous Sclerosis Drug Market

34. Recent Developments In The Tuberous Sclerosis Drug Market

35. Tuberous Sclerosis Drug Market High Potential Countries, Segments and Strategies

• 35.1 Tuberous Sclerosis Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Tuberous Sclerosis Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Tuberous Sclerosis Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer